China Still ‘Attractive’ For Danaher Despite $50M VBP Drag

Danaher Expects Business Development In China To Regain Momentum In The Second Half Of 2025

 
• By Shubham Singh
  
Despite the near-term disruption, Danaher remains optimistic about the long-term growth prospects in the region.

More from Strategy

More from Medtech Insight